| Women without distant metastases | |||
|---|---|---|---|
| Characteristic | At diagnosis | At five years | At ten years |
| Women | 6338 | 5137 | 4406 |
| Extent of disease | |||
| Localised (T1–T3 N0) | 3885 (61%) | 3372 (66%) | 2949 (67%) |
| Regional (T4 or N+) | 2453 (39%) | 1765 (34%) | 1457 (33%) |
| Age (years) | |||
| Median (interquartile range) | 59 (49–69) | 64 (55–74) | 68 (59–77) |
| Under 40 | 386 (6%) | 82 (2%) | 22 (1%) |
| 40–49 | 1223 (19%) | 637 (12%) | 225 (5%) |
| 50–59 | 1725 (27%) | 1293 (25%) | 918 (21%) |
| 60–69 | 1423 (22%) | 1419 (28%) | 1325 (30%) |
| 70 or more | 1581 (25%) | 1706 (33%) | 1916 (43%) |
| Tumour morphology | |||
| Invasive ductal | 4874 (77%) | 3933 (77%) | 3387 (77%) |
| Invasive lobular/mixed | 806 (13%) | 668 (13%) | 553 (13%) |
| Other | 658 (10%) | 536 (10%) | 466 (11%) |
| Treatment‐defined estrogen receptor status (prior endocrine therapy)* | — | 3451 (70%) | 2808 (67%) |
| Any endocrine or chemotherapy records | 5190 (82%) | 4117 (80%) | 3475 (79%) |
| Remoteness of residence | |||
| Major city | 4555 (72%) | 3688 (72%) | 3175 (72%) |
| Inner regional | 1353 (21%) | 1099 (21%) | 923 (21%) |
| Outer regional | 400 (6%) | 323 (6%) | 285 (6%) |
| Remote/very remote | 30 (0.5%) | 27 (0.5%) | 23 (1%) |
| Postcode‐level socio‐economic status | |||
| 1 (most disadvantaged) | 1056 (17%) | 836 (16%) | 718 (16%) |
| 2 | 1266 (20%) | 1003 (20%) | 817 (19%) |
| 3 | 1213 (19%) | 987 (19%) | 853 (19%) |
| 4 | 1182 (19%) | 964 (19%) | 841 (19%) |
| 5 (least disadvantaged) | 1621 (26%) | 1347 (26%) | 1177 (27%) |
| Country of birth | |||
| Australia/New Zealand | 4330 (71%) | 3451 (70%) | 2931 (70%) |
| Other | 1769 (29%) | 1469 (30%) | 1263 (30%) |
| Missing data | 239 | 217 | 212 |
| Subsequent non‐breast primary cancer during follow‐up | 525 (8%) | 397 (8%) | 255 (6%) |
*
Based on number of women for whom endocrine therapy was dispensed in the preceding period, expressed as a proportion of the number with linked Pharmaceutical Benefits Scheme records (6151 women).